Friday, June 19, 2026
BIO pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High BIOTECH 3 DAYS AWAY

BIO — 2026 — San Diego Convention Center, San Diego, USA

Biocom is excited to announce the upcoming Noven Pharmaceuticals Partner Day on Wednesday, June 10. To explore potential collaboration opportunities through 1:1 meetings with Noven Pharmaceuticals leadership, please submit an application by Monday, May 25.Representatives from Nov

San Diego Convention Center, San Diego, USA June 22 – June 25, 2026
20,000+ Attendees
5 Presentations
5 Companies
1 Drugs
All Events

Presentation data updated Jun 6, 2026, 5:32 AM UTC

Nova Event Impact Score
71 /100
  • Media coverage 20/20
  • Speaker quality 20/20
  • Pipeline relevance 1/20
  • Historical influence 20/20
  • Company participation 10/20

Key Takeaways

Key Themes

biotechBIOPipeline announcementsPartnership deals

Key Companies

NovartisAstraZenecaSummit TherapeuticsClimb BioImmunityBio

Key Drugs

pelacarsen

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Investors & analysts

Full Schedule

5 presentations

LATE BREAKER

LATE-BREAKER Jun 22

Phase III Lp(a)HORIZON study of pelacarsen: top-line results

Novartis$NVS pelacarsen Phase Iii cardiovascular disease (elevated lipoprotein(a))
INVESTOR IMPACT: ★★★★★ 5/5

PLENARY

PLENARY Jun 25

Business update and 2026 financial results with pipeline progress

ImmunityBio$IBRX oncology
INVESTOR IMPACT: ★☆☆☆☆ 1/5

ORAL

ORAL Jun 23

Initial readouts from ongoing trials in immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy

Climb Bio$CLMB Phase Ii immunoglobulin A nephropathy, primary membranous nephropathy
INVESTOR IMPACT: ★★☆☆☆ 2/5
ORAL Jun 24

Phase III data readout for a key trial in oncology (partnered with Summit Therapeutics)

Summit Therapeutics$SMMT Phase Iii oncology
INVESTOR IMPACT: ★★★★☆ 4/5
ORAL Jun 24

Phase III data readouts for key studies in oncology (H1 and H2 2026)

AstraZeneca$AZN Phase Iii oncology
INVESTOR IMPACT: ★★★★☆ 4/5